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Abstract
Riccardin D, a macrocyclic bisbibenzyl isolated from Chinese liverwort Dumortiera hirsute, has been proved to have
inhibitory effect on biofilms formation of Candida albicans in in vitro study. Our present study aims to investigate the in vivo
effect and mechanisms of riccardin D against C. albicans biofilms when used alone or in combination with clinical using
antifungal agent fluconazole. XTT reduction assay revealed riccardin D had both prophylactic and therapeutic effect against
C. albicans biofilms formation in a dose-dependent manner when using a central venous catheter related infective animal
model. Scanning electron microscope and laser confocal scanning microscope showed that the morphology of biofilms was
altered remarkably after riccardin D treatment, especially hypha growth inhibition. To uncover the underlying molecular
mechanisms, quantitative real-time RT-PCR was performed to observe the variation of related genes. The downregulation of
hypha-specific genes such as ALS1, ALS3, ECE1, EFG1, HWP1 and CDC35 following riccardin D treatment suggested riccardin
D inhibited the Ras-cAMP-Efg pathway to retard the hypha formation, then leading to the defect of biofilms maturation.
Moreover, riccardin D displayed an increased antifungal activity when administered in combination with fluconazole. Our
study provides a potential clinical application to eliminate the biofilms of relevant pathogens.
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Introduction
Biofilms are surface-associated structured microbial communi-
ties surrounded by a matrix of extracellular polymeric substances
produced by the microorganism cells [1,2]. Biofilms can form on
both natural and artificial surfaces, displaying altered gene phe-
notypes compared with planktonic cells [3]. Biofilms forming on
implanted medical device can cause bloodstream infection,
resulting in high rate of morbidity and mortality among hospi-
talized patients, which has become a major clinical problem [4].
Candida species, which also have the ability to develop biofilms
on surfaces, represent the fourth most common cause of
bloodstream infections in the United States [4]. Of all cases of
candidemias, C. albicans accounts for up to 63% [5]. Predisposing
factors for Candida infections include immunosuppressive therapy,
broad spectrum antibiotics therapy, HIV infection, diabetes, old
age, and use of indwelling devices, such as intravascular catheters
[6,7]. In ICU patients, a total of 72% to 87% of bloodstream
infections, including candidemia, are considered to be catheter
related [8,9], with the common mechanism of the fungal cells
adherence and biofilms formation on the surfaces of catheters [10].
Infections often result in the removal of the infected catheters in
order to eradicate a potential nidus of bloodstream infection [11].
However, catheter removal is not always feasible for patients with
coagulopathy or limited vascular access and is associated with
increased healthcare expenses as well as complications related to
catheter replacement, thus in view of these situations drug
treatment is still to be considered [12]. It was proved, however,
biofilms-associated cells show resistance against antimicrobials
therapy as well as against host defense agents such as phagocytes
and antibodies [13–16]. For this reason, measures need to be taken
to treat with biofilms-associated infection and high levels of drug
resistance, and new antifungal agent development is necessary and
feasible.
Riccardin D (RCD), a macrocyclic bisbibenzyl isolated from
Chinese liverwort Dumortiera hirsute by our team (Figure 1), has
been proved in our previous investigations to have the antifungal
activity against C. albicans either in planktonic form or in biofilms,
with the possible mechanism of hypha formation inhibition [17–
20]. However, what we have known about RCD is based on in vitro
studies, and here, we report the efficacy of RCD against C. albicans
biofilms developed in vivo by using a clinically relevant animal
model of C. albicans biofilms-associated catheter infection. We
determined the antifungal efficacy of RCD when administered
alone or in combination with traditional antifungal agent
fluconazole (FLC), and we also utilized quantitative real-time
RT-PCR (qPCR) to investigate the underlying molecular
mechanisms of its anti-biofilms effect.
Methods
Ethics statement
The use of all the animals (rabbits) in this research was reviewed
and approved by Experimental Animals Ethics Committee,
Center for Drug Evaluation and Research, Shandong Pharma-
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under protocol NO. SCXK20080002.
Organism
C. albicans isolate YEM 30 (kindly donated by Dr Michael La
Fleur in Northeastern University of USA) was used in this study
and stored in medium supplemented with 10% (vol./vol.) glycerol
at 280uC. The minimal inhibition concentrations (MICs) of FLC
and RCD against this strain in planktonic form were 0.5 mg/ml
and 16 mg/ml, respectively, according to the Clinical and
Laboratory Standards Institute (CLSI) M27-A3 method; while
after biofilms formed, the sessile minimal inhibition concentrations
(SMICs) were over 64 mg/ml and 128 mg/ml, respectively. Before
infection, the strain was grown on YPD solid medium containing
2% agar at 30uC and subcultured in liquid YPD medium (2%
tryptone, 1% yeast extract, 2% glucose) in an orbiter shaker with
130 rpm at 30uC.
Reagent preparation
RCD and FLC were dissolved in the solvent dimethylsulfoxide
(DMSO) at the concentration of 20,480 mg/ml as stock solutions
and frozen at 220uC. The content of DMSO in the test volume
was below 0.5%. The stock solutions were diluted with
heparinized saline before use as working solutions. RCD, isolated
from liverwort plant D. hirsute by our team, has a purity of 98.6%,
as determined by high performance liquid chromatography
(HPLC). FLC was obtained from the Institute of Biopharmaceu-
ticals of Shandong, China. Propidium iodide (PI) and fluorescein
diacetate (FDA) were purchased from Sigma (St Louis, MO,
USA).
Animal models development and biofilms formation
New Zealand White rabbits weighing 2.5 to 3.0 kg were used
for all procedures (Animal Centre, Shandong Institute of
Pharmaceutical Industry). Animal models were established using
a modified method described before [21,22]. Briefly, an
intravenous catheter with a heparin cap (Becton Dickinson
Medical Devices Co., Ltd.) was precut by the needle side and
sterilized by ethylene oxide. Before the catheter was inserted into
the venous, a rectangular polyethylene film (1 cm62 cm) sterilized
by 75% alcohol was curled gently and put into the lumen of the
catheter with a stainless steel needle under aseptic condition.
Sterilization of the film was verified by colony count. Rabbits were
given intravenous anesthesia with pentobarbital sodium (3%, w/v,
40 mg/kg of body weight). At the same time, the animals were
given penicillin and gentamycin to prevent the surgical site
infection. The right cervical, shoulder, and scapular regions were
shaved with an electric clipper and sterilized with 75% alcohol
followed by betadine solution. An incision was made in the right
anterolateral cervical region, exposing the external jugular vein. A
segment of the external jugular vein, just distal to the bifurcation of
the internal and external maxillary veins, was freed from
subcutaneous fat. The catheter full of sterile heparinized saline
was inserted into the vein caudally 3 cm, with the tip placed in the
right anterior vena cava. The proximal and distal ligatures were
tied, and blood was withdrawn to test catheter patency. The
catheter was then flushed with heparinized saline. Passing a
hemostat cephalad through a 1.0-cm incision in the intrascapular
region to the external jugular vein incision site created a
subcutaneous tunnel. The heparin lock device at the end of the
catheter was pulled out through the subcutaneous tunnel. The
neck incision and the catheter exit were closed by using 3-0 vicryl
sutures and sterilized with betadine solution.
Catheters were infected 24 hours after their placement to allow
a conditioning period for deposition of host protein on the surface
of the polyethylene film. A standard 300 ml of inoculum (the lumen
volume of the catheter) consisting of 10
7 CFU of C. albicans
YEM 30, 100 U of heparin (Changzhou Qianhong biochemical
pharmaceutical Co., LTD, China), and 0.9% sterile normal saline
was prepared. The mixture was ‘‘locked’’ in the internal lumen of
the catheter and allowed to dwell for a special period of time.
Then the inoculum was removed, and replaced with heparinized
saline. During the experiment, the catheter was flushed with
300 ml of heparinized saline (100 U) every 24 hours. The animals
were observed twice a day for signs of distress or inflammation
after the surgery.
Inhibitory effect of RCD against C. albicans biofilms in
vivo
To determine the prophylactic and therapeutic effect of RCD
against C. albicans biofilms in vivo, we administered RCD solutions
to the catheterized animals before and after biofilms formed. The
anti-biofilms effect of RCD used in combination with traditional
antifungal agent FLC was also studied to evaluate whether the
compound had sensitizing effect to the latter.
For the first experiment, RCD were administered once at the
early stage of C. albicans biofilms development to test the
prophylactic effect of RCD against biofilms growth. The animals
were catheterized and infected as described above. After 4 hours
attachment, the inoculums were removed, and 300 ml of drug
solutions containing 100 U of heparin were injected slowly
through the heparin caps. The rabbits were randomized into six
groups, each consisting of six animals. Group I received 300 mlo f
heparinized (100 U) saline as the control. Group II, III and IV
received 300 ml of RCD solution (at the concentrations of 8 mg/
ml, 16 mg/ml and 64 mg/ml, respectively) containing 100 U of
heparin. Group V and VI received 300 ml of FLC solution (4 mg/
ml), and FLC (4 mg/ml) plus RCD solution (16 mg/ml) containing
100 U of heparin, respectively, to investigate the antifungal effect
of RCD against C. albicans biofilms when used in combination with
FLC. The concentrations of FLC and RCD were based on the
result of an in vitro study (data not shown). We used FLC with the
concentration 8 times higher than the in vitro MIC. The drug
solutions were locked in the catheter lumens for 8 h, at which time
the drug solutions were removed and replaced with heparinized
saline. After 24 h from the initiation of infection, animals were
sacrificed humanely.
For the second experiment, to assess the therapeutic effect of
RCD against pre-existing C. albicans biofilms, the drug solutions (at
the concentrations of 8 mg/ml, 16 mg/ml and 64 mg/ml, respec-
tively) were injected after 24 hours of C. albicans infection. The
rabbits were randomized into four groups, each consisting of six
animals. Animals received 300 ml of heparinized saline instead of
Figure 1. Molecular structure of riccardin D.
doi:10.1371/journal.pone.0035543.g001
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catheters for 8 h per day for 5 days consecutively. For daily
catheters treatment, RCD lock solutions were replaced by 300 ml
of heparinized saline. If the drug solution was difficult to withdraw
from the catheter, it could be flushed into the systemic circulation.
After the animals were sacrificed, the catheters were removed
under sterile conditions and the polyethylene films were taken out.
The films were made smooth gently and flushed with phosphate-
buffered saline (PBS, pH 7.4) to remove blood and nonadherent C.
albicans cells. The specimens were cut into two segments, one for
quantitative culture, and the other for confocal laser scanning
microscopy examination. Before quantitative culture, the speci-
mens were put into 200 ml sterile PBS, sonicated at 40,000 Hz
(Bransonic 1510; Branson Ultrasonics Corp., Danbury, Conn.) for
15 min and then vortexed for 30 s vigorously. The quantitative
results were expressed as the mean CFU per milliliter from 6
animals. Based on prior clinical studies, catheters growing 10
2 CFU
or more of C. albicans were considered infected [22]. We selected
samples randomly for scanning electron microscopy (SEM).
Quantitative determination of biofilms
For quantitation, after the specimens were flushed with PBS,
sonicated and vortexed, the suspension was removed to microtiter
plates. We used a 2,3-bis(2-methoxy-4-nitro-5-sulfo-phenyl)-2H-
tetrazolium-5-carboxanilide (XTT) reduction assay as previously
described to quantify C. albicans cells [23]. Briefly, XTT (Sigma)
was prepared as a saturated solution at 0.5 mg/ml in Ringer’s
lactate and filter sterilized and stored at 270uC. Prior to each
assay, menadione (10 mM prepared in acetone; Sigma) was added
to obtain a final concentration of 1 mM. A 100 ml aliquot of XTT-
menadione was then added to each well, and microtiter plates
were incubated in the dark for 2 h at 37uC. The colorimetric
change (a reflection of the metabolic activity of cells within the
biofilms) was measured in a BIO-TEK ELX800 microtiter plate
reader at 490 nm. The antifungal effect was measured by
comparing the reduction in the mean absorbance of the drug
treated wells to that of the drug free control. The experiment was
performed in triplicate.
Catheter biofilms imaging
Scanning electron microscopy. Biofilms were assessed after
catheters infection with or without drug challenge by SEM
observation. Briefly, the infected polyethylene films were flushed
with PBS and fixed in 2.5% glutaraldehyde to be prepared for
SEM observation. Samples were subsequently washed in distilled
water, dehydrated gently by washing in a series of ethanol alcohol
(30% for 10 min, 50% for 10 min, 70% for 10 min, 95% for
10 min and 100% for 10 min), and air dried in a desiccator prior
to sputter coating with gold. Afterwards, specimens were mounted
on the aluminium stubs and coated with gold in a low-pressure
atmosphere with an ion sputter coater (Jeol JFC1 100: Jeol, Tokyo,
Japan). The topographic features of the biofilms were visualized
with a scanning electron microscope (Philips XL30CP) in high
vacuum mode at 10 kV and the images were processed for display
with Photoshop software (Version 5.0, Adobe Systems Inc.,
Mountain View, CA).
Confocal laser scanning microscopy. The morphology
and activity of C. albicans biofilms were observed by a confocal
laser scanning microscope (Zeiss 710). Before observation, the
specimens were stained with FDA and PI as described previously
[24,20]. All metabolically active yeast cells were stained with the
FDA dye and visualized with a diffusely distributed green
fluorescence, whereas those with damaged membranes were
stained with PI and showed fluorescent red. Thus cell viability
could be assessed using this dye method. Stained specimens were
transferred to a glass slide covered with a coverslip disk for
observation. Images were processed for display by using Axiovision
3.x software (Zeiss).
Quantitative RT-PCR
Quantitative real-time reverse transcription-PCR (RT-PCR)
was used to compare mRNA abundances of the genes of interest.
C. albicans biofilms were formed as described above. RCD solution
at the concentration of 64 mg/ml was administered to the catheter
after 4 hours attachment and allowed to dwell for 18 hours, while
catheters receiving heparinized saline alone worked as the
comparison. We did 3–4 animals to obtain enough mRNA for
analysis for each experiment. Animals were sacrificed after
48 hours from infection. Total RNA was extracted from the 48-
h-old biofilms with or without RCD challenge. The TaqMan
MGB probe and primer sets were designed for the target genes
ALS1, ALS3, ECE1, EFG1, HWP1 and CDC35, using Primer
Express 1.5 software (Applied Biosystems, Foster City, Calif.).
Primer sequences used for amplification of the genes are listed in
Table 1. The total RNAs were respectively isolated using the hot
phenol method as described elsewhere [24]. Reactions were
performed in duplicate according to the kit manufacturer’s
instructions. We used ACT1 as the internal control. The
experiment was carried out in triplicate. The quantitative data
analysis was completed using an Eppendorf Mastercycler Real
Time PCR System. The comparative expression value was
calculated using the following formula: fold change=2
2DDCt.
Statistical evaluation
Data were described as mean 6 SD. The mean CFUs from
quantitative catheter cultures were compared by the Student’s t-
test using StatView version 5.0.1 software (SAS Institute, Cary,
N.C.). P,0.05 was considered significant.
Results
Animal models development
We established central venous catheter (CVC) -associated C.
albicans biofilms infective rabbit model according to the method
Table 1. Primers used for RT-PCR experiments.
primer sequence Tm (6C)
ALS1-F 59-ATTGGTAAAGTAACTGTACCA-39 60.0
ALS1-R 59-CACATTGAATATGCCATGTG-39 60.0
ALS3-F 59-AGGTTGTTCTTGGGTTTCTG-39 55.7
ALS3-R 59-TGTAGATGGAGAAGTTG-39 53.7
ECE1-F 59-GCTGGTATCATTGCTGATAT-39 60.0
ECE1-R 59-TTCGATGGATTGTTGAACAC-39 60.0
EFG1-F 59-TATGCCCCAGCAAACAACTG-39 57.8
EFG1-R 59-TTGTTGTCCTGCTGTCTGTC-39 57.8
HWP1-F 59-TGGTGCTATTACTATTCCGG-39 55.75
HWP1-R 59-CAATAATAGCAGCACCGAAG-39 55.75
CDC35-F 59-TTCATCAGGGGTTATTTCAC-39 53.7
CDC35-R 59-CTCTATCAACCCGCCATTTC-39 57.8
ACT1-F 59-AGCTTTGTTCAGACCAGCTGATT-39 60.0
ACT1-R 59-TTGACCAAACCACTTTCAACTCC-39 60.0
doi:10.1371/journal.pone.0035543.t001
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rabbits appeared well during all of the study. After the animals
were sacrificed, the polyethylene films in catheters were removed,
flushed with PBS, stained by using Gram’s method and observed
under an inverted microscope (Olympus). Biofilms on the surface
were unevenly distributed, with the cells, hypha, and matrix
stained blue as shown in Figure 2. In the 10-hour-old biofilms,
both yeast and hypha could be observed with a thin layer, and not
much matrix. After 24 h development, multiple-layered mature
biofilms consisting of an extensive network of yeast cells and hypha
embedded in abundant extracellular matrix formed. The biofilms
continued to grow and proliferate after 48 h and 72 h. At the late
stage of development, the biofilms were embeded with so thick
matrix that they could not be observed clearly.
Efficacy of RCD on C. albicans biofilms formed in vivo
Using quantitative culture technique, we evaluated the
prophylactic efficacy of RCD against C. albicans biofilms developed
in vivo when used alone or combined with FLC, and the
therapeutic effect after 5-day-treatment of RCD as well. Results
were shown in Figure 3. When administered after 4 hours
attachment of C. albicans cells, RCD showed an inhibition effect
against biofilms growth in a concentration dependent manner
(Figure 3 (A)). The cell counts in the control group (catheters were
treated with heparinized saline) was (1.5610
661.4610
5) CFU.
After the treatment with RCD at the concentrations of 8 mg/ml,
16 mg/ml and 64 mg/ml for 8 h, the cell counts were
(7.2610
563.1610
5) CFU, (2.6610
561.4610
5) CFU and
(5.6610
462.8610
4) CFU, respectively. The cell counts were
Figure 2. Inverted microscope images of C. albicans biofilms formed in vivo. C. albicans biofilms after 10 h (A), 24 h (B), 48 h (C) and 72 h (D)
of development (61,600).
doi:10.1371/journal.pone.0035543.g002
Figure 3. Antifungal effect of riccardin D against C. albicans biofilms formed in vivo. (A) Riccardin D at different concentrations (8 mg/ml,
16 mg/ml and 64 mg/ml), fluconazole (4 mg/ml), or riccardin D (16 mg/ml) combined with fluconazole (4 mg/ml) was administered once to 4-hour-old
biofilms and were allowed to dwell in the catheter for 8 h. Animals in control group received heparinized saline instead of drug solution. After 24 h
growth of biofilms, the specimens were removed for quantification. (B) Riccardin D at different concentrations (8 mg/ml, 16 mg/ml and 64 mg/ml)
were administered to the 24-hour-old biofilms, and allowed to dwell for 8 h per day for 5 days consecutively. Animals in control group received
heparinized saline instead of drug solution. After treatment of RCD for 5 days, the specimens were removed for colony count.
doi:10.1371/journal.pone.0035543.g003
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high concentrations compared with that in the control group
(P=0.0276 and P=0.0003, respectively). The quantification of
cells treated with FLC alone or in combination with RCD were
(1.2610
464.5610
3) CFU and (3.8610
361.5610
3) CFU, respec-
tively (P=0.0004), suggesting a remarkably decrease in C. albicans
cells and an increased efficacy of drug combination than used
alone, which was accordance with the results in vitro (data not
shown).
For the 5-day-treatment experiment, the control, the low dose
and medium dose group each had one catheter clotted, so results
were obtained from the unclotted catheters. Against the 24-hour-
old biofilms, RCD showed good antifungal effect in a dose-
dependent manner. As shown in Figure 3 (B), the results indicated
about 4 log10, 3 log10 and 1.6 log10 reduction in biofilms fungal
load for the high dose, medium dose and low dose group
compared with the control group (P,0.0001, P=0.0002 and
P=0.0015, respectively). Biofilms were eliminated totally in 3
catheters in high dose group and 2 in medium dose group.
We evaluated the toxicity of RCD by observing animals’
reactions and measuring the body weights. The animals showed
no obvious adverse reaction or significant loss of body weight
during drug use. Similarly, according to our previous work, RCD
treatment was generally well tolerated by mice except for slight
vein stimulation when administered via tail vein (not published),
indicating the safety of RCD. In this study, drug solutions were
injected to catheters locally by ‘‘antibiotic-lock’’ technique rather
than administered systemically, therefore, systemic and severe
drug toxicity to animals could be avoided.
Biofilms imaging
Catheters with or without drug challenge were removed from
the animals, and the polyethylene films were taken out as the
specimens for SEM and confocal laser scanning microscopy
images. Figure 4 shows SEM images of in vivo C. albicans biofilms
with or without RCD (64 mg/ml) treatment. The biofilms in the
control group was in large quantity, but in uneven distribution in
the polyethylene films. After 24 h of growth in vivo, the biofilms
consisted of a lot of yeast cells and hypha embedding in much
extracellular matrix. We could find some red blood cells not
flushed from the biofilms, having similar size with C. albicans cells
but different phenotype (Figure 4 (A)). For the biofilms treated with
RCD at the early stage, however, it was difficult to find biofilms
under SEM because of its small amout. In the remaining biofilms,
C. albicans cells were shrinked, without much hypha or thick
extracellular matrix around the cells as the biofilms in the control
group (Figure 4 (B)). For the biofilms treated with RCD for 5 days,
what could be seen only were some dead cells, fractured hypha
and remaining ECM (Figure 4 (C)).
We also investigated the activity of biofilms cells by staining with
FDA and PI, as shown in Figure 5. Images showed that live and
dead cells could be distinguished under the confocal laser scanning
microscope. For the biofilms without drug treatment, strong green
fluorescent was observed because FDA binded to metabolically
active cells, suggesting the cells in biofilms were viable (Figure 5
(A)). We found different morphology when biofilms were treated
with RCD solutions at the concentrations of 16 mg/ml and 64 mg/
ml (Figure 5 (B) and (C)). The cells were stained green or red, with
fewer cell counts and hypha compared with the control, indicating
the cells in biofilms were inviable because of the damage by the
drugs. When using RCD (16 mg/ml) combined with FLC (4 mg/
ml), the cells were stained with red color, much smaller and fewer,
and with fewer hypha in the visual field (Figure 5 (E)) compared
with those challenged by FLC alone (Figure 5 (D)). It could be
concluded from these findings that RCD has antifungal efficacy
against C. albicans biofilms, and there was an increased anti-
biofilms effect when RCD and FLC were used in combination.
Quantitative RT-PCR
To elucidate the potential molecular mechanism, we extracted
mRNA from cells isolated from the polyethylene films and then
utilized qPCR to analyze the expression of hypha-related genes
under the treatment of RCD. We did several animals to obtain
enough mRNA for analysis, with 14 mg of total C. albicans mRNA
isolated from the films. The data showed that C. albicans hypha-
related genes ALS1, ALS3, ECE1, EFG1, HWP1, and hypha
formation regulator CDC35, were all down-regulated following the
treatment of RCD at the concentration of 64 mg/ml. The results
were shown in Figure 6.
Discussion
Natural products have been an important source of innovative
therapeutic agents in various conditions, including infectious
diseases [25]. Our team has been committed to extracting and
screening compounds with antifungal activity from liverworts
plants. Among these compounds, bisbibenzyls were proved to have
a wide range of biological activities such as antifungi, antioxida-
tion, antivirus, antibacteria and cytotoxicity [26–29]. In our
previous research, bisbibenzyls showed antifungal effects through
stimulating the synthesis of farnesol via upregulation of Dpp3,
suggesting a potential antifungal application of this kind of
compounds [30]. The macrocyclic bisbibenzyl RCD, extracted
from Chinese liverwort Dumortiera hirsute, structurally consisted of
two biphenyl bonds linked by diaryl ether bonds and phenolic
Figure 4. Scanning electron microscopy images of C. albicans biofilms formed in vivo (62,000). (A) biofilms treated with heparinized
saline; (B) biofilms after riccardin D treatment for 8 h. The inoculums of YEM 30 were removed after 4 hours growth, and riccardin D solution at the
concentration of 64 mg/ml was injected into the catheter and locked in the lumen for 8 h; (C) biofilms after 5-day-treatment of riccardin D. The
inoculums of YEM 30 were removed after 24 hours growth, and riccardin D solution at the concentration of 64 mg/ml was injected into the catheter
and locked in the lumen for 8 h for 5 days consecutively. The bar is 15 mm for the three panels.
doi:10.1371/journal.pone.0035543.g004
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C. albicans in either planktonic or biofilms states [17,19,20]. RCD
also showed synergistic effect when used in combination with FLC
against C. albicans in vitro, with the possible mechanism of
interfering with the FLC-targeted ergosterol biosynthesis pathway
[31]. Our understanding about the inhibition effect of RCD
against C. albicans planktonic cells or biofilms is based on in vitro
studies, while these experiments could not simulate the in vivo
environment of the infection and host immune system exactly. In
this study, we established an in vivo CVC-related C. albicans biofilms
infective rabbit model to investigate the drug effect. We found that
RCD has both prophylactic and therapeutic effect on C. albicans
biofilms-associated infection by downregulating the expression of
hypha specific genes. Also, when used in combination with
traditional antifungal FLC, RCD could increase the efficacy
Figure 5. Confocal laser scanning microscopy images of C. albicans YEM 30 biofilms developed in vivo (6630). After 4 hours of C.
albicans YEM 30 infection, the inoculums were removed, and riccardin D was administered alone or in combination with fluconazole and allowed to
dwell in the catheters for 8 h. The specimens were removed after the animals sacrifice, washed with PBS (pH 7.4) and stained with fluorescein
diacetate (FDA) and propidium iodide (PI). Cell viability could be assessed using confocal laser scanning microscopy because healthy cells with an
intact membrane were stained fluorescent green, whereas those with damaged membranes stained fluorescent red. (A) Biofilms after 24 h of
development without drug treatment; (B) Biofilms challenged by riccardin D at the concentration of 16 mg/ml; (C) Biofilms treated with riccardin D at
the concentration of 64 mg/ml; (D) Biofilms treated with fluconazole at the concentration of 4 mg/ml; (E) Biofilms treated with riccardin D (16 mg/ml)
and fluconazole (4 mg/ml) when used in combination.
doi:10.1371/journal.pone.0035543.g005
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efficacy and mechanisms of the anti-biofilms functions of RCD.
According to an in vitro study, C. albicans biofilms formation
progresses in three development phases: early phase (0–11 h),
intermediate phase (12–30 h) and mature phase (31–72 h) [32].
Based on the preliminary experiments, we found biofilms
formation was related with strains and materials to which fungal
cells adhered (data not shown). Using the CVC-related infective
animal model, we obtained biofilms at different growth times of
10 h, 24 h, 48 h and 72 h. Observed with an inverted microscopy,
the yeast cells and hypha were embeded in the dense extracellular
matrix, with the structures not so clear as those formed in vitro.A s
to the 72-hour-old biofilms, we could not even distinguish yeast
cells from the abundant extracellular matrix. The 24-hour-old
biofilms yielded fungal cells of about 10
6 CFU. The cell counts of
biofilms changed little after 24 hours growth.
In the antifungal efficacy experiments, we administered the drug
solutions to catheters locally by ‘‘antibiotic-lock’’ technique
because it could form high concentration in the lumen locally to
obtain higher antifungal effect than administered via veins. When
injected in the early stage of biofilms development (4-hour-old),
RCD was proved to have an inhibitory activity on C. albicans
biofilms formed in vivo when used alone or in combination with
FLC, indicating a prophylactic effect on biofilms-associated
infection (Figure 3). When administered to the 24-hour-old
biofilms for 5 days consecutively, RCD showed good anti-biofilms
activity, especially in the medium or high dose groups. We could
conclude from Figure 3 that RCD inhibited biofilms growth in a
dose dependent style. Figure 5 indicated that RCD could inhibit
the metabolic activity of fungal cells in biofilms. It has ever been
demonstrated that RCD displayed a function in inhibiting biofilms
formation by retarding fungal hypha formation [17]. In this in vivo
experiment, although it is difficult to distinguish and count hypha
because of the dense extracellular matrix and remaining tissues of
animals, we could draw a similar conclusion as the in vitro
experiment on biofilms inhibition of RCD.
The yeast-to-hypha transition of C. albicans biofilms is regulated
by various impact factors, including carbohydrates, amino acids,
salts, pH changes, temperature increases, but no single environ-
mental factor could be defined as uniquely significant in
stimulating the morphological switch [33]. To investigate the
mechanisms of inhibitory effect of RCD on C. albicans biofilms in
vivo, we selected genes interested for study further, including ALS1,
ALS3, ECE1, EFG1, HWP1 and CDC35. Previous study has proved
that hypha formation in C. albicans biofilms is stimulated by the
Ras-cAMP-Efg signalling pathway. In this cAMP dependent
pathway, the GTP-bound form of Ras is capable of stimulating
adenylate cyclase encoded by the gene CDC35, resulting in the
increase of cAMP level that promotes specific gene activation,
including EFG1, which induce the expression of the hypha specific
genes such as ALS3 and HWP1, and then mediate the hypha
formation [34]. In C. albicans, the agglutinin-like sequence (ALS)
genes have been revealed to have close relationship with biofilms
formation [35,36]. It was proved that overexpression of ALS3 leads
to an increase in biofilms mass [37], while overexpression of
HWP1, the necessary factor for normal biofilms formation in vitro
and in vivo could effectively restores the ability of a bcr1D null
strain to form biofilms on murine mucosal surfaces [38–40]. In this
study, we found all the genes were downregulated after RCD
treatment compared with the control, indicating RCD affects C.
albicans biofilms formation by inhibiting Ras-cAMP-Efg signalling
pathway.
Our findings confirm the conclusion drawn from the in vitro
study about the inhibition effect of RCD against C. albicans biofilms
by using an in vivo CVC-related infective animal model. That is,
RCD has activity on biofilms development when used alone or
combined with FLC, with the mechanism of inhibition of hypha
formation. Therefore, it could be concluded that RCD is a new
kind of antifungal agent with potential in clinical application.
Further researches need to be carried out to clarify the precise
correlation between the upstream regulation genes and hypha-
specific proteins.
Figure 6. Expression of C. albicans biofilms-related genes. Different expression of genes ALS1, ALS3, ECE1, EFG1, HWP1 and CDC35 following
the treatment with riccardin D (64 mg/ml) for 18 h. The biofilms grew for 48 h totally. ACT1 works as an internal control.
doi:10.1371/journal.pone.0035543.g006
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